ADC Therapeutics
ADCT
56 hedge funds and large institutions have $813M invested in ADC Therapeutics in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 11 closing their positions.
390% more call options, than puts
Call options by funds: $9.44M | Put options by funds: $1.93M
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
1% more capital invested
Capital invested by funds: $801M → $813M (+$11.6M)
0.92% more ownership
Funds ownership: 42.79% → 43.7% (+0.92%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less funds holding
Funds holding: 59 → 56 (-3)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$9.81M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$9.22M |
| 3 |
BlackRock
New York
|
+$6.98M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$4.96M |
| 5 |
AA
ALPS Advisors
Denver,
Colorado
|
+$2.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MICM
Matthews International Capital Management
San Francisco,
California
|
-$14.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.06M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.93M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$1.91M |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
-$1.8M |
ADCT Hedge Fund Activity: Q2 2021 in Review
56 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q2 2021, worth a combined $813M — up 1.4% from $801M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ADCT and 8 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 21 added.
The largest buyer was AllianceBernstein, adding an estimated $9.81M. The largest seller was Matthews International Capital Management, exiting entirely with an estimated $14.8M sold.
- 56 institutional investors held ADC Therapeutics (ADCT) as of Q2 2021, down from 59 in Q1 2021.
- Funds reported $813M of ADC Therapeutics stock for Q2 2021, up 1.4% quarter-over-quarter.
- 8 funds opened new ADC Therapeutics positions in Q2 2021 and 11 closed out, a net change of -3 holders.
- The largest ADC Therapeutics buyer in Q2 2021 was AllianceBernstein, an estimated $9.81M added.
- The largest ADC Therapeutics seller in Q2 2021 was Matthews International Capital Management, an estimated $14.8M sold.
Based on aggregated 13F filings for Q2 2021.